BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 16172569)

  • 21. Somatostatin receptor scintigraphy with 111In-pentetreotide in non-functioning gastroenteropancreatic neuroendocrine tumors.
    Schillaci O; Spanu A; Scopinaro F; Falchi A; Corleto V; Danieli R; Marongiu P; Pisu N; Madeddu G; Delle Fave G; Madeddu G
    Int J Oncol; 2003 Dec; 23(6):1687-95. PubMed ID: 14612942
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Significance of a Single-Time-Point Somatostatin Receptor SPECT/Multiphase CT Protocol in the Diagnostic Work-up of Gastroenteropancreatic Neuroendocrine Neoplasms.
    Ruf J; von Wedel F; Furth C; Denecke T; Stelter L; Steffen IG; Schütte K; Arend J; Ulrich G; Klose S; Bornschein J; Apostolova I; Amthauer H
    J Nucl Med; 2016 Feb; 57(2):180-5. PubMed ID: 26609177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The utility of 99mTc-EDDA/HYNIC-TOC scintigraphy for assessment of lung lesions in patients with neuroendocrine tumors.
    Pavlovic S; Artiko V; Sobic-Saranovic D; Damjanovic S; Popovic B; Jakovic R; Petrasinovic Z; Jaksic E; Todorovic-Tirnanic M; Saranovic D; Micev M; Novosel S; Nikolic N; Obradovic V
    Neoplasma; 2010; 57(1):68-73. PubMed ID: 19895175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Value of Somatostatin Receptor Scintigraphy (SRS) in Patients with NETG1/G2 Pancreatic Neuroendocrine Neoplasms (p-NENs).
    Kolasińska-Ćwikła AD; Konsek SJ; Buscombe JR; Maciejkiewicz K; Cichocki A; Roszkowska-Purska K; Sawicki Ł; Tenderenda M; Cwikla JB
    Nucl Med Rev Cent East Eur; 2019; 22(1):1-7. PubMed ID: 30276787
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Additional lesions detected in therapeutic scans with 177Lu-DOTATATE reflect higher affinity of 177Lu-DOTATATE for somatostatin receptors.
    Mirzaei S; Bastati B; Lipp RW; Knoll P; Zojer N; Ludwig H
    Oncology; 2011; 80(5-6):326-9. PubMed ID: 21791941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Preliminary clinical application of 99Tcm-HYNIC-TOC imaging in somatostatin receptor-positive tumors].
    Li F; Chen LB; Jing HL; Du YR; Chen F
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Oct; 25(5):563-6. PubMed ID: 14650159
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imaging of neuroendocrine gastro-entero-pancreatic tumours using radiolabelled somatostatin analogues.
    Chiti A; van Graafeiland BJ; Savelli G; Ferrari L; Seregni E; Castellani MR; Bombardieri E
    Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S190-4. PubMed ID: 10604128
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours.
    Chiti A; Fanti S; Savelli G; Romeo A; Bellanova B; Rodari M; van Graafeiland BJ; Monetti N; Bombardieri E
    Eur J Nucl Med; 1998 Oct; 25(10):1396-403. PubMed ID: 9818279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biokinetics and dosimetry in patients of 99mTc-EDDA/HYNIC-Tyr3-octreotide prepared from lyophilized kits.
    González-Vázquez A; Ferro-Flores G; Arteaga de Murphy C; Gutiérrez-García Z
    Appl Radiat Isot; 2006 Jul; 64(7):792-7. PubMed ID: 16542847
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A visual and semi-quantitative assessment of (99m)Tc-EDDA/HYNIC-TOC scintigraphy in differentiation of solitary pulmonary nodules.
    Płachcińska A; Mikołajczak R; Kozak J; Rzeszutek K; Kuśmierek J
    Nucl Med Rev Cent East Eur; 2004; 7(2):143-50. PubMed ID: 15968601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of tumour size and uptake of 99mTc-octreotide on radio-guided surgery for neuroendocrine tumors.
    Hodolic M; Fettich J; Rubello D
    Minerva Endocrinol; 2009 Jun; 34(2):89-96. PubMed ID: 19471233
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Octreo-SPECT/CT imaging for accurate detection and localization of suspected neuroendocrine tumors.
    Perri M; Erba P; Volterrani D; Lazzeri E; Boni G; Grosso M; Mariani G
    Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):323-33. PubMed ID: 18480741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of 99mTc-HYNIC-Tyr3-octreotide scintigraphy in neuroendocrine tumors based on localization of the primary tumor.
    Jimenez Londoño GA; García Vicente AM; Soriano Castrejon AM; Gómez López OV; Palomar Muñoz A; Vega Caicedo CH; Cordero García JM
    Minerva Endocrinol; 2016 Mar; 41(1):10-8. PubMed ID: 25582872
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radio-guided surgery with the use of [99mTc-EDDA/HYNIC]octreotate in intra-operative detection of neuroendocrine tumours of the gastrointestinal tract.
    Hubalewska-Dydejczyk A; Kulig J; Szybinski P; Mikolajczak R; Pach D; Sowa-Staszczak A; Fröss-Baron K; Huszno B
    Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1545-55. PubMed ID: 17653543
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Indium-111-DTPA-phenyl-pentetreotide somatostatin receptors' scintigraphy in the evaluation of patients with suspected gastro-entero-pancreatic tumors. Comparison with computerized tomography].
    Gerasimou GP; Aggelopoulou T; Papanastasiou E; Konidari-Dedousi E; Prousalidis I; Psarrakos K; Siountas A; Molybda E; Gotzamani-Psarrakou A
    Hell J Nucl Med; 2007; 10(3):209-14. PubMed ID: 18084669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Octreotide imaging plus bone scintigrams to optimally localize gastroenteropancreatic neuroendocrine tumors.
    Le Duc-Pennec A; Thol C; Cavarec M; Le Rest C; Turzo A; Guillo P; Bizais Y
    Clin Nucl Med; 2003 Jan; 28(1):5-8. PubMed ID: 12493952
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Microcystic Serous Cystadenoma Masquerading as Pancreatic Neuroendocrine Tumor on 99m Tc-HYNIC-TOC SPECT/CT.
    Cai W; Dong Y; Zhao T; Dong A; Zhao Q
    Clin Nucl Med; 2024 Feb; 49(2):e87-e89. PubMed ID: 38048519
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years' experience.
    Hubalewska-Dydejczyk A; Fröss-Baron K; Mikołajczak R; Maecke HR; Huszno B; Pach D; Sowa-Staszczak A; Janota B; Szybiński P; Kulig J
    Eur J Nucl Med Mol Imaging; 2006 Oct; 33(10):1123-33. PubMed ID: 16721571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of recurrent pancreatic primitive neuroectodermal tumor by tc-99m hydrazinonicotinyl-tyr3-octreotide scan.
    Jing H; Li F; Chen L; Zhang T; Zhao Y
    Clin Nucl Med; 2011 Jan; 36(1):54-5. PubMed ID: 21157213
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Uptake in the pancreatic uncinate process on the 111In-octreotide scintigraphy: How to distinguish physiological from pathological uptake?
    Ait Boudaoud A; Verges B; Petit JM; Tatulashvili S; Cochet A; Humbert O
    Nucl Med Commun; 2017 Sep; 38(9):737-743. PubMed ID: 28704340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.